About 30% of all human cancers are driven by mutations of the RAS family of genes. The RAS Initiative endeavors to better understand the RAS oncogene and discover its vulnerabilities to treat RAS-related cancers.

We are home to unique scientific expertise and technological capabilities available nowhere else. The Technical Services Program through the Partnership Development Office makes some of these capabilities and services readily available to the external research community at-cost to advance biomedical research around the world.